Seminars in arthritis and rheumatism最新文献

{"title":"Racial disparity of lung cancer risk in people with rheumatoid arthritis","authors":"Yi-Sheng Jhang , Yu-Jung Su , Hui-Chin Chang , Shih-Chi Yang , Shiu-Jau Chen , Shuo-Yan Gau","doi":"10.1016/j.semarthrit.2025.152702","DOIUrl":"10.1016/j.semarthrit.2025.152702","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152702"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing the PEIR Framework and PEIRS-22 to facilitate improved and sustainable patient engagement in OMERACT","authors":"Caitlin Jones ,&nbsp;Clayon Hamilton ,&nbsp;Peter Tugwell ,&nbsp;Shawna Grosskleg ,&nbsp;Catherine Hofstetter ,&nbsp;Ben Horgan ,&nbsp;Alison Hoens ,&nbsp;Dorcas Beaton","doi":"10.1016/j.semarthrit.2025.152704","DOIUrl":"10.1016/j.semarthrit.2025.152704","url":null,"abstract":"<div><h3>Background</h3><div>OMERACT (Outcome Measures in Rheumatology) is an international initiative focused on improving outcome measurement in rheumatology research, fostering collaboration among PRPs, clinicians, and researchers to develop Core Outcome Sets. The 22-item Patient Engagement In Research Scale (PEIRS-22) is a tool designed to measure the level of meaningful patient engagement and guide efforts towards improvement.</div></div><div><h3>Aim</h3><div>1) To describe the current profile of patient engagement at OMERACT using the scores generated by the PEIRS-22 and 2) to assess the validity of the PEIRS-22 within the OMERACT group of PRPs.</div></div><div><h3>Methods</h3><div>We administered the PEIRS-22 to assess the level of meaningful engagement of PRPs with OMERACT. We compared the scores with self-rated participant engagement, and asked open ended questions to investigate the validity of the tool in the OMERACT PRP population.</div></div><div><h3>Results</h3><div>Overall engagement was meaningful and correlated to self-reported level of engagement. However, there were components and items that were flagged as priorities for improvement (Convenience, Benefits and Team Environment, and specifically items PR11: I participated in making decisions about the project, T2: I was an equal partner in the research project team, and SU1: I received sufficient support to contribute to the project.</div></div><div><h3>Conclusion</h3><div>This study highlights the validity of the PEIRS-22 within OMERACT and reveals satisfactory levels of meaningful PRP engagement. As OMERACT continues to learn and evolve, the PEIRS-22 will be integral in developing a structured and consistent approach to patient engagement.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152704"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remission in gout is possible: 5-year follow-up in the NOR-Gout study","authors":"Till Uhlig ,&nbsp;Johan Stjärne ,&nbsp;Lars Fridtjof Karoliussen ,&nbsp;Joe Sexton ,&nbsp;Tron Eskild ,&nbsp;Sella Aarrestad Provan ,&nbsp;Espen André Haavardsholm ,&nbsp;Hilde Berner Hammer","doi":"10.1016/j.semarthrit.2025.152698","DOIUrl":"10.1016/j.semarthrit.2025.152698","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the performance of remission definitions for gout in an observational treat-to-target patient cohort with 5 years of follow-up.</div></div><div><h3>Methods</h3><div>Inclusion criteria were crystal proven gout with increased serum urate levels and a flare. Remission was determined according to the 2016 preliminary gout remission definition, a modified preliminary definition with more lenient thresholds for the individual variables pain due to gout and patient global assessment of gout disease activity, and the simplified definition without patient reported outcomes. Linear mixed models were used to compare quality of life with SF-36 physical (PCS) and mental (MCS) components and structural damage with semiquantitative dual energy tomography (DECT) across patients fulfilling and not fulfilling each remission definition.</div></div><div><h3>Results</h3><div>Data were analysed from 211 patients (mean age 56.4 years, 95.3 % males) included in an intensive one-year treat-to-target intervention with follow-up at 1, 2, and 5 years. The frequency of remission increased for both the preliminary definition at 1, 2 and 5 years (4.6 %, 22.1 %, and 42.8 %), the modified preliminary definition (5.1 %, 28.4 %, and 44.1. %) and the simplified definition (7.7 %, 45.4 %, and 58.6 %)(<em>p</em> &lt; 0.001 for all definitions). The simplified definition identified more patients in remission than the preliminary and the modified preliminary definition at years 2 and 5. All three definitions discriminated for SF-36 MCS, PCS or DECT.</div></div><div><h3>Conclusion</h3><div>Remission in gout after urate lowering therapy was seldom after 1 but high after 5 years and was highest for the simplified definition. Remission definitions showed concurrent validity for quality of life and structural changes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152698"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set","authors":"Wils Nielsen ,&nbsp;Fadi Kharouf ,&nbsp;Carolina Munoz Grajales ,&nbsp;Aarabi Thayaparan ,&nbsp;Melanie Anderson ,&nbsp;Vibeke Strand ,&nbsp;Lee Simon ,&nbsp;Dennisse Bonilla ,&nbsp;Eric Morand ,&nbsp;Julian Thumboo ,&nbsp;Martin Aringer ,&nbsp;Marta Mosca ,&nbsp;Ian Bruce ,&nbsp;Elektra J. Papadopoulos ,&nbsp;Karina D. Torralba ,&nbsp;Laura Patricia Whitall-Garcia ,&nbsp;Cheryl F. Rosen ,&nbsp;Ioannis Parodis ,&nbsp;Alfred Kim ,&nbsp;Maya Desai ,&nbsp;Zahi Touma","doi":"10.1016/j.semarthrit.2025.152684","DOIUrl":"10.1016/j.semarthrit.2025.152684","url":null,"abstract":"<div><h3>Objective</h3><div>To identify candidate Systemic Lupus Erythematosus (SLE) domains from the literature for consideration towards the development of the SLE Core Outcome Set.</div></div><div><h3>Methods</h3><div>This was a comprehensive scoping literature review of SLE clinical trials and systematic reviews published since 2010. Studies were identified from 5 databases and were screened for eligibility. Candidate domains were extracted from the included studies. Candidate domains were winnowed and binned by the Outcome Measures in Rheumatology (OMERACT) SLE Advisory Group.</div></div><div><h3>Results</h3><div>Of the 4063 studies identified, 507 met inclusion criteria and proceeded to data extraction. Multiple domains and items were extracted, which winnowing and binning reduced to 25 candidate domains.</div></div><div><h3>Conclusion</h3><div>The 25 candidate domains cover the important aspects of SLE and the 4 core areas of disease impact according to OMERACT framework. The 25 candidate domains constitute a feasible and manageable number of domains to proceed with to the core domain consensus stage that covers the wide range of impact of SLE. The candidate domains will be supplemented by ongoing qualitative research with patients living with SLE to identify additional domains before proceeding to the consensus stage.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152684"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant cell arteritis – New treatment targets at the horizon","authors":"Jens Thiel","doi":"10.1016/j.semarthrit.2025.152686","DOIUrl":"10.1016/j.semarthrit.2025.152686","url":null,"abstract":"<div><div>Increasing insights into the pathogenesis of giant cell arteritis (GCA) identified a large number of new treatment targets. Very recently clonal hematopoesis, immune ageing processes associated with inflammation and dysregulated immune checkpoints have been linked to the pathogenesis of GCA. Based on pathopyhsiological insights new treatment options such as Janus kinase inhibitors or IL-17A blocking antibodies are currently tested in GCA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152686"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies in anti-MDA5 antibody-positive interstitial lung disease patients: A multicenter retrospective cohort study in China","authors":"Bi Chen ,&nbsp;Bin Xi ,&nbsp;Hongxia Xin ,&nbsp;Ruyi Zou ,&nbsp;Yaqiong Tian ,&nbsp;Qi Zhao ,&nbsp;Xin Yan ,&nbsp;Xiaohua Qiu ,&nbsp;Yujuan Gao ,&nbsp;Yin Liu ,&nbsp;Min Cao ,&nbsp;Hanyi Jiang ,&nbsp;Ping He ,&nbsp;Juan Chen ,&nbsp;Hourong Cai","doi":"10.1016/j.semarthrit.2025.152700","DOIUrl":"10.1016/j.semarthrit.2025.152700","url":null,"abstract":"<div><div>The aim of this study was to assess the 2017 EULAR/ACR classification criteria performance for determining idiopathic inflammatory myopathies (IIMs) in a cohort of patients with anti-MDA5 antibody-positive IIM-related interstitial lung disease (anti-MDA5+IIM-ILD). The outcomes of patients, who did not meet the EULAR/ACR criteria, and who had interstitial pneumonia and exhibited an autoimmune phenotype associated with anti-MDA5 positivity were also investigated.</div></div><div><h3>Methods</h3><div>This retrospective study recruited adult patients from four hospitals in China who were diagnosed with anti-MDA5 antibody-positive IIM-related interstitial lung disease. Data on disease manifestations, laboratory findings, and imaging findings were collected through electronic medical records. The performance and consistency of the 2017 EULAR/ACR classification criteria were compared with those of the Bohan/Peter criteria combined with Sontheimer's CADM criteria. Additionally, this study evaluated the performance of incorporating anti-MDA5 antibodies into the EULAR/ACR criteria and explored the criteria proposed by Casal-Domingez based on myositis-specific antibodies (MSAs). Finally, clinical characteristics and prognoses were compared between patients with MDA5+IIM-ILD who met the EULAR/ACR criteria and those who did not meet the EULAR/ACR criteria.</div></div><div><h3>Results</h3><div>A total of 250 patients with anti-MDA5-related IIM-ILD, including those with dermatomyositis (DM, 23.6 %) and clinically amyopathic dermatomyositis (CADM, 76.4 %), were recruited. Of these, 175 (70 %) and 64 (25.7 %) patients met the EULAR/ACR and Bohan/Peter criteria, respectively. According to Sontheimer's CADM criteria, 60.4 % of patients could be classified according to the Bohan and Peter criteria. Thirty percent of the anti-MDA5 antibody-positive patients did not meet the EULAR/ACR criteria but met the IPAF criteria. The sensitivity of the EULAR/ACR criteria increased to 99.2 % when anti-JO-1 antibodies were replaced with anti-MDA5 antibodies. In this cohort, a sensitivity of 100 % was obtained using the Casal-Domingez criteria. There were no significant differences in clinical characteristics or prognoses between MDA5+IIM-ILD patients who met the EULAR/ACR criteria, those who did not meet the criteria, and those who met the IPAF criteria.</div></div><div><h3>Conclusion</h3><div>Approximately 30 % of clinically diagnosed anti-MDA5 antibody-positive IIM-ILD patients cannot be classified according to the EULAR/ACR criteria, suggesting that such patients should be managed as IIM-ILD patients. Modifying the existing criteria by including other MSAs, such as anti-MDA5 antibodies, as one of the scoring criteria is recommended. Future IIM guidelines should consider incorporating ILD into the diagnostic criteria.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152700"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Autoantibody response in rheumatoid arthritis; what makes it unique?","authors":"Rene E.M. Toes","doi":"10.1016/j.semarthrit.2025.152699","DOIUrl":"10.1016/j.semarthrit.2025.152699","url":null,"abstract":"<div><div>Many autoimmune diseases respond well to therapies targeting B cells, emphasizing the importance of autoreactive B cells in disease induction and progression. In some cases, autoantibodies from plasma cells are the main effectors, while in others, memory B cells are thought to modulate inflammatory responses through antigen presentation or cytokine secretion. Tolerance mechanisms usually prevent the development of autoantibodies, but when these systems fail, autoimmunity and subsequent autoimmune diseases can arise. Understanding the dynamics of autoreactive B cell responses is crucial for delineation the pathogenic pathways underlying disease. Rheumatoid arthritis (RA) is a prototypic autoimmune disease featuring autoreactive B cell responses against post-translationally modified (PTM) proteins. Especially, the Anti-Citrullinated Protein Antibody (ACPA) response, the autoimmune response hallmarking RA, is well characterized over the last two decades. ACPA target citrullinated proteins and their presence is associated with more severe disease progression. In recent years, it has become apparent that ACPA are very promiscuous and able to recognize both human and microbial PTM proteins. Likewise, it is now clear that these antibodies often carry Fab glycans that could, potentially, boost B cell activation and/or be involved in evasion of tolerance mechanisms. Although subjected to tolerance checkpoint, new technologies have shown that the secreted ACPA repertoire is highly polyclonal, unique to each patient, but also dominated by a few ACPA clones.</div><div>In this synopsis, these and other findings are discussed. Overall, these shed light on the complexity and evolving nature of the ACPA response in RA, unveiling new insights into autoreactive B cell behavior.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152699"},"PeriodicalIF":4.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct appearances of circulatory and secretory IgM demarcated by CD5L","authors":"Albert J.R. Heck","doi":"10.1016/j.semarthrit.2025.152683","DOIUrl":"10.1016/j.semarthrit.2025.152683","url":null,"abstract":"<div><div>IgM is an important human immunoglobulin present in our blood, but also in mucosa and body fluids such as saliva, tears and breast milk. In this manuscript Heck describes recent findings, namely that the CD5L protein is always attached to circulatory IgM but not to secretory IgM</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152683"},"PeriodicalIF":4.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B suppressor cells and protective autoantibodies","authors":"Rikard Holmdahl","doi":"10.1016/j.semarthrit.2025.152687","DOIUrl":"10.1016/j.semarthrit.2025.152687","url":null,"abstract":"<div><div>Recently the importance of B cells has been highlighted for therapy of several autoimmune diseases including rheumatoid arthritis (RA). Still, the functional role of B cells and antibodies in the disease process are unclear. Using animal models, antibodies specifically binding cartilage are pathogenic, but it has also recently been shown that both B cells and antibodies could be protective. These have specificities that are similar to B cells and autoantibodies detected in humans, including antibodies to citrullinated proteins and collagen type II, and may play an important role hindering an inflammatory attack, whereafter pathogenic B cells and antibodies are functionally more important to initiate and drive the clinically observable disease.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152687"},"PeriodicalIF":4.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the Wnt pathway for the treatment of Osteoarthritis of the knee","authors":"Nancy E. Lane","doi":"10.1016/j.semarthrit.2025.152662","DOIUrl":"10.1016/j.semarthrit.2025.152662","url":null,"abstract":"<div><div>Both epidemiologic and preclinical models of OA provide strong support for modulation of the Wnt signaling pathway as a druggable target for painful knee OA. This paper reviews the clinical studies that have been performed with Wnt signaling modulating agents for knee OA treatment and makes recommendations to study earlier disease and administer treatments for a longer duration.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152662"},"PeriodicalIF":4.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}